title: Levetiracetam: a long-term follow-up study of efficacy and safety.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of long-term add-on treatment with levetiracetam 1,000-4,000 mg/day.
  
  
  METHODS
  In this multicenter, open-label follow-up study, 505 patients, from 10 European countries, who had benefited from previous add-on treatment with levetiracetam in a clinical trial or compassionate-use program were enrolled; 274 (54.3%) stayed to the end. Most then continued levetiracetam by prescription or in a named patient program, where it was not yet commercially available. Mean treatment duration was 1,045 days (range: 24 days to >7 years). Median daily dosage was 3,000 mg/day (range: 250-6,000 mg/day), with 250 (49.5%) patients receiving levetiracetam for >3 years.
  
  
  RESULTS
  Median total and partial seizure frequency per week over the evaluation period were 0.8 and 0.7; seizure frequency per week was generally stable over time and remained low. There was a probability of 6.6% of remaining seizure-free for the first 3 years, and of 18.9% of having a seizure-free period of at least 3 years at any time. Most adverse events were mild or moderate and unrelated to study drug. Levetiracetam was well tolerated, and provided stable seizure control during long-term treatment.
authors.affiliation: Universitätsklinikum Bonn, Klinik für Epileptologie, Bonn, Germany. juergen.bauer@ukb.uni-bonn.de
authors.forename: J
authors.initials: J
authors.lastname: Bauer
authors.forename: E
authors.initials: E
authors.lastname: Ben-Menachem
authors.forename: G
authors.initials: G
authors.lastname: Krämer
authors.forename: W
authors.initials: W
authors.lastname: Fryze
authors.forename: S
authors.initials: S
authors.lastname: Da Silva
authors.forename: D G A
authors.initials: DG
authors.lastname: Kasteleijn-Nolst Trenité
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam